Dear Reader,

Of all people, I never would have guessed Dave Lashmet…

Dave's our biotech expert.

He's the editor of our most elite and expensive research service, Stansberry Venture.

Dave's a shy guy.

He lives on a remote island off the coast of Washington that's typically only accessible by ferryboat.

So I was surprised to receive a video message from Dave last week telling me how excited he was about our "Melt Up Millionaire" Project.

Dave said, "I think what Steve has to say about the end of a bull market is pretty awesome… so I'm on his side not Porter's."

Dave even allowed us to use one of his biotech recommendations for our model portfolio. (Typically, you'd pay $5,000 for a recommendation like this).

I can't say much about it here, but I will tell you this…

It's a pharmaceutical stock with a current market cap of $1 billion…

Dave believes that if the company's drug clears its upcoming Phase 3 trial with the FDA, it could easily be worth $10 billion.

(And it's been 95% successful with patients who used it so far…)

Steve and Dave think this one stock could easily return hundreds of percent very quickly.

And it's just one of the investments in our new "Melt Up Millionaire" model portfolio.

Remember, we're swinging for the fences with this new project.

Our goal is to return weighted gains of at least 100% in the next 12 months.

If not, you get full credit back… plus a free year of our work… guaranteed.

The only catch is you must start building your positions soon if you expect to see these gains…

And we'll only extend discounted access for new members for a limited time.

To learn more about the "Melt Up Millionaire" Project, click here. 

Regards,

Brett Eversole
Senior Analyst, Stansberry Research